Question to the Department of Health and Social Care:

To ask the Secretary of State for Health, what recent assessment his Department has made of the adequacy of treatment and support provision available through the NHS for patients of myelodysplastic syndromes blood cancers.

The Department has made no such assessment. The responsibility for commissioning services for patients with myelodysplastic syndromes blood cancers is split across NHS England and clinical commissioning groups (CCGs). NHS England is responsible for commissioning the specialised aspects of the pathway, such as blood and bone marrow transplants. CCGs are responsible for commissioning more local services, such as blood transfusions and support services.